Alzheimer's

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial
Eli Lilly Says New Data Can Potentially Provide Path To Improved Donanemab Profile By Lower Risk Of Imaging Abnormalities In Patients With Early Alzheimer's
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings

Alzheimer's Recent News

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no statistical significance in key outcomes.
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Cassava Sciences is cooperating with DOJ and SEC investigations involving its Alzheimer's drug simufilam. An internal committee is examining new SEC information, while the company advances its Phase 3 trials independently of the implicated researcher.
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a critical inspection report by the Food and Drug Administration.
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this 
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed mixed on Tuesday as a disparate set of corporate earnings dampened the existing euphoria over the possibility of a slowdown in rate hikes.
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
Silo Pharma Inc.
Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open — Apple, Biogen Stocks In Focus
U.S. stocks could struggle for direction on Wednesday after the market struggled en route to a mixed close in the previous session. Volatility could be the order of the day as another batch of Fed speeches are in the pipeline.
Why Biogen Stock Is Up 40% Today
Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday.
Benzinga's Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
IGC THC-Drug For Alzheimer's Symptoms Proved Safe & Effective, Pending FDA Approval For More Trials
India Globalization Capital, Inc.
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Biogen Inc. (NASDAQ: BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Adu
Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
After months of wait, Biogen Inc. (NASDAQ: BIIB) has finally achieved success by taking its controversial Alzheimer's treatment past the finish line.
Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate
Biogen Inc (NASDAQ: BIIB) shares were soaring Wednesday in reaction to an FDA  briefing document released ahead of Friday's Adcom meeting on the investigational Alzheimer's drug aducanumab, an amyloid beta-targeting antibody.
Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'
Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.
Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump
Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed.
VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Chinese Regulators Tentatively Approve Novel Alzheimer's Drug — The First Since 2003
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved